Search
Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease.
MSK experts believe that giving the targeted drug asciminib to patients with chronic myeloid leukemia at the beginning of their treatment offers them a better chance of being cured.
Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. Fellows are chosen based on excellence demonstrated by their thesis proposal examinations.
Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution.
Memorial Sloan Kettering's Boards of Overseers and Managers have announced the creation of the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs and have named the first two incumbents: Sloan Kettering Institute's Grégoire Altan-Bonnet and Songhai Shi.
James Rothman, who receives this year’s Nobel Prize in Physiology or Medicine together with Randy Schekman and Thomas Südhof, conducted more than a decade of his seminal research at Memorial Sloan Kettering.
Meet Mary Wu, a patient financial services specialist at Memorial Sloan Kettering Westchester.
MSK researchers have found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer.
New research on an experimental drug provides hope for better responses to immunotherapy.